Qtr 1 2010 compared to Qtr 1 2009:
"This increase was driven primarily by higher Tamiflu(R) (oseltamivir phosphate) royalties from F. Hoffmann-La Roche Ltd of $246.3 million in the first quarter of 2010, compared to Tamiflu royalties of $33.2 million in the first quarter of 2009, resulting from increased sales related to influenza pandemic planning initiatives worldwide."
Source: http://investors.gilead.com/phoenix.zhtml?c=69964&p=irol-newsArticle&ID=1415271&highlight=
4th qtr Results:
"The increases were driven primarily by higher Tamiflu(R) (oseltamivir phosphate) royalties from F. Hoffmann-La Roche Ltd of $194.1 million and $392.7 million in the fourth quarter and full year of 2009, respectively, compared to Tamiflu royalties of $16.0 million and $155.5 million in the fourth quarter and full year of 2008, respectively, resulting from increased sales related to pandemic planning initiatives worldwide."
Source: http://investors.gilead.com/phoenix.zhtml?c=69964&p=irol-newsArticle&ID=1379225&highlight=
Therefore, Qtr 1 2010 compared to Qtr 4 2009:
$246.3 million vs $194.1 million
Interesting, the above is indicating an increase in Qtr 1!
Regards
SP
- Forums
- ASX - By Stock
- BTA
- gileads tamiflu sales up
gileads tamiflu sales up, page-3
-
-
- There are more pages in this discussion • 11 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
CC9
Chariot Corporation (ASX:CC9) refines Black Mountain strategy, launching Pilot Mine to seize U.S. lithium opportunity
NEWS
Breakthrough programs slash healthcare events, driving a significant A$1.8M+ annual revenue boost